title: [Update on current care guidelines: multiple sclerosis].
abstract: Treatment for relapsing-remitting multiple sclerosis (RRMS) is initiated upon fulfillment of new McDonald 2010 criteria for RRMS. Patients with clinically isolated syndrome and at high-risk for RRMS are followed by magnetic resonance imaging to confirm the diagnosis of RRMS as early as possible. Interferon-beta and glatiramer acetate are the first-line immunomodulating drugs (IMD) for RRMS. If the disease is active according to clinical or MRI evaluation during the first-line IMD treatment, fingolimod or natalizumab may be considered as second-line therapies. IMD is discontinued upon the transition of RRMS to secondary progressive phase.
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D000068876:Fingolimod Hydrochloride; D000068717:Glatiramer Acetate; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016899:Interferon-beta / Q000627:therapeutic use; D008279:Magnetic Resonance Imaging; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000175:diagnosis* / Q000188:drug therapy*; D000069442:Natalizumab; D010455:Peptides / Q000627:therapeutic use; D017410:Practice Guidelines as Topic; D011409:Propylene Glycols / Q000627:therapeutic use; D013110:Sphingosine / Q000031:analogs & derivatives / Q000627:therapeutic use
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D007155:Immunologic Factors; D007166:Immunosuppressive Agents; D000069442:Natalizumab; D010455:Peptides; D011409:Propylene Glycols; D000068717:Glatiramer Acetate; D016899:Interferon-beta; D000068876:Fingolimod Hydrochloride; D013110:Sphingosine